Polls

In this edition of You Make the Call, your patient presents with worsening plaque psoriasis (>8% BSA) now affecting his scalp and bilateral upper extremities after failing effective treatment with narrowband UV-B and topical corticosteroid combination therapy. How would you approach treatment?

The decision to start a patient with psoriasis onto a systemic agent for disease management is an important conversation between provider and patient. When considering a biologic for the treatment of plaque psoriasis, what is the most important factor in your clinical decision?

Immunomodulating therapies can help a majority of patients receiving the therapy achieve and maintain Psoriasis Area and Severity Index 100 scores for short- and long-term periods of time. How have newer biologics impacted your practice? Let us know!

How has your clinic’s transition to teledermatology platforms been during the COVID-19 pandemic?

What are some of the concerns about the coronavirus that you are hearing from patients?

Submit your feedback in our poll.

What do you think the biggest challenges for dermatology will be in 202?

What medicines, products, or therapies have revolutionized your practice and improved patient outcomes?